.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Novartis
McKinsey
Citi
Julphar
Teva
Farmers Insurance
Moodys
Cerilliant
Chubb

Generated: November 22, 2017

DrugPatentWatch Database Preview

Amgen Company Profile

« Back to Dashboard

What is the competitive landscape for AMGEN, and when can generic versions of AMGEN drugs launch?

AMGEN has two approved drugs.

There are nine US patents protecting AMGEN drugs.

There are two hundred and thirty-five patent family members on AMGEN drugs in forty-nine countries and seven supplementary protection certificates in seven countries.

Summary for Amgen

International Patents:235
US Patents:9
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004RXYesNo► Subscribe► SubscribeY ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004RXYesNo► Subscribe► SubscribeY ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► SubscribeY ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004RXYesYes► Subscribe► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► SubscribeY ► Subscribe
Amgen Inc
CORLANOR
ivabradine hydrochloride
TABLET;ORAL206143-001Apr 15, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Amgen Inc
CORLANOR
ivabradine hydrochloride
TABLET;ORAL206143-002Apr 15, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Amgen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for AMGEN drugs

Drugname Dosage Strength Tradename Submissiondate
cinacalcet hydrochloride
Tablets30 mg, 60 mg and 90mg
SENSIPAR
3/10/2008

Non-Orange Book Patents for Amgen

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,391,210 Abrasive article► Subscribe
5,858,684 Method of screening calcium receptor-active molecules► Subscribe
5,962,314 Calcium receptor-active molecules► Subscribe
6,211,244 Calcium receptor-active compounds► Subscribe
6,001,884 Calcium receptor-active molecules► Subscribe
5,763,569 Calcium receptor-active molecules► Subscribe
5,688,938 Calcium receptor-active molecules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Amgen Drugs

Country Document Number Estimated Expiration
Portugal724561► Subscribe
Germany602006002624► Subscribe
Guatemala200600088► Subscribe
Slovenia1663182► Subscribe
China1067550► Subscribe
Hong Kong1046900► Subscribe
European Patent Office1707562► Subscribe
Russian Federation2194499► Subscribe
Argentina045637► Subscribe
Georgia, Republic ofP20084465► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Amgen Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0029France► SubscribePRODUCT NAME: CINACALCET; REGISTRATION NO/DATE: EU/01/04/292/001-012 20041022
0199Netherlands► Subscribe
C/GB05/031United Kingdom► SubscribePRODUCT NAME: CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT OR COMPLEX THEREOF; REGISTERED: UK EU/1/04/292/001 20041022; UK EU/1/04/292/002 20041022; UK EU/1/04/292/003 20041022; UK EU/1/04/292/004 20041022; UK EU/1/04/292/005 20041022; UK EU/1/04/292/006 20041022; UK EU/1/04/292/007 20041022; UK EU/1/04/292/008 20041022; UK EU/1/04/292/009 20041022; UK EU/1/04/292/010 20041022; UK EU/1/04/292/011 20041022; UK EU/1/04/292/012 20041022; UK EU/1/04/293/001 20041022; UK EU/1/04/293/002 20041022; UK EU/1/04/293/003 20041022; UK EU/1/04/293/004 20041022; UK EU/1/04/293/005 20041022; UK EU/1/04/293/006 20041022; UK EU/1/04/293/007 20041022; UK EU/1/04/293/008 20041022; UK EU/1/04/293/009 200410
C020/2005Ireland► SubscribeSPC020/2005: 20060407, EXPIRES: 20191021
2005 00027Denmark► Subscribe
1203761/01Switzerland► SubscribePRODUCT NAME: CINACALCETUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56965 27.10.2004
182Luxembourg► Subscribe91182, EXPIRES: 20191022
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Cerilliant
Queensland Health
Medtronic
Moodys
AstraZeneca
Cipla
Fish and Richardson
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot